The biotechnology sector is filled with high-potential growth stocks. With advancements in artificial intelligence (AI), biotech remains at the cutting edge of medical and scientific innovation, driving breakthroughs in gene therapy, immunotherapy, and personalized medicine. Furthermore, early-stage biotech stocks offer growth exposure for investors with a high-risk appetite.
Zevra Therapeutics (ZVRA) and Syndax Pharma (SNDX) have earned a “Strong Buy” rating from Wall Street analysts, signaling their confidence in the company’s future growth prospects. Let’s take a closer look at why these two biotech stocks have earned this bullish rating.
